Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation Pfizer’s stock has declined 7.3% so far this year against an increase of 2.4% for the industry.

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...